The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial).
 
Ke-Feng Ding
No Relationships to Disclose
 
Yue Liu
No Relationships to Disclose
 
Yanqiao Zhang
No Relationships to Disclose
 
Rongbo Lin
No Relationships to Disclose
 
Xiaobing Chen
No Relationships to Disclose
 
Junye Wang
No Relationships to Disclose
 
Mudan Yang
No Relationships to Disclose
 
Xiujuan Qu
No Relationships to Disclose
 
Yunfeng Li
No Relationships to Disclose
 
Jiayi Li
No Relationships to Disclose
 
Weisheng Zhang
No Relationships to Disclose
 
Yong Mao
No Relationships to Disclose
 
Ziwei Wang
No Relationships to Disclose
 
Zhenyang Liu
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Jian Lei
No Relationships to Disclose
 
Ye Xu
No Relationships to Disclose
 
Yi Jiang
No Relationships to Disclose
 
Zhanyu Pan
No Relationships to Disclose
 
Liangjun Zhu
No Relationships to Disclose
 
ANCHOR Trial's Group
No Relationships to Disclose